This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVO Stock Crashes 22% After 2025 View Cut: More Downside Ahead?
by Ahan Chakraborty
Novo Nordisk stock plunges 22% after slashing 2025 sales and profit outlooks, citing weak GLP-1 drugs' uptake and rising competition.
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
by Zacks Equity Research
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
by Zacks Equity Research
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
by Ahan Chakraborty
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $32.07, representing a +1.39% change from its previous close.
Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
by Sundeep Ganoria
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) reached $31.29 at the closing of the latest trading day, reflecting a +2.93% change compared to its last close.
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
by Kinjel Shah
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
by Ahan Chakraborty
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.52, representing a -5.86% change from its previous close.
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
by Ahan Chakraborty
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
by Kinjel Shah
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
by Zacks Equity Research
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
by Ahan Chakraborty
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
by Ahan Chakraborty
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
Viking Therapeutics, Inc. (VKTX) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $26.01, indicating a -1.03% shift from the previous trading day.
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
by Ahan Chakraborty
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
by Ahan Chakraborty
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
by Kinjel Shah
LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $28.59, representing a -1.26% change from its previous close.